Skip to main content
  • 116428 (ZOSTER-039: Study to evaluate safety and immunogenicity of GSK - A Phase III, randomised, observer-blind, placebo controlled, multicentre study to assess the safety and immunogenicity of GSK Biologicals’ Herpes Zoster HZ/su candidate vaccine when administered intramuscularly on a two-dose schedule to adults aged 18 years and older with haematologic malignancies.
  • 3D Vis study - A pilot study of case studies to assess whether the use of three dimensional (3D) computer generated imaging to analyses de-identified MRI and CT images can be used to enhance patient understanding of neurological disease.
  • 64091742PCR2001 - Galahad - A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
  • A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients with Advanced Solid Malignancies - A Phase I, Open-label, Multi-center, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of HMPL-453 in Patients with Advanced Solid Malignancies.
  • A Multicenter, Open-Label, Phase 1b/2 Study To Evaluate Safety And Efficacy Of Avelumab In Combination With Chemotherapy With Or Without Other Anticancer Immunotherapies As First-Line Treatment In Pat - A Phase 1b/2, open label, multicenter, safety and clinical activity study of avelumab in combination with chemotherapy as first-line treatment of adult patients with locally advanced or metastatic solid tumors.
  • A Phase 1a/1b multicentre, open-label, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, and anti-tumor activity of AK105 in subjects with advance solid tumors - A Phase 1a/1b multicentre, open-label, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, and anti-tumor activity of AK105 in subjects with advance solid tumors
  • A Phase 1b Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination with Pembrolizumab in Adult Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - A Phase 1b Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination with Pembrolizumab in Adult Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
  • A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma (CITADEL - 203) - A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma (CITADEL - 203)
  • A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer - A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer
  • A Phase 3 Randomised, Double-blind Active-controlled study Evaluating Momelotinib vs. Ruxolitinib in Subjects with primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-essential Thrombocythem - A Phase 3 Randomised, Double-blind Active-controlled study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
  • A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib - A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib
  • A Phase Ib, Open-Label, Multicenter Study Evaluating The Safety And Efficacy Of Ipatasertib In Combination With Atezolizumab And Paclitaxel Or Nab-Paclitaxel In Patients With Locally Advanced Or Metas - A Phase Ib, Open-Label, Multicenter Study Evaluating The Safety And Efficacy Of Ipatasertib In Combination With Atezolizumab And Paclitaxel Or Nab-Paclitaxel In Patients With Locally Advanced Or Metastatic Triple- Negative Breast Cancer
  • A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia (CLL) who have responded t - A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia (CLL) who have responded to induction therapy
  • A pilot randomised controlled trial of oral varenicline versus oral naltrexone for the treatment of alcohol dependence - AR_A pilot randomised controlled trial of oral varenicline versus oral naltrexone for the treatment of alcohol dependence
  • A pilot study to explore the safety of pyridostigmine in constipated palliative care patients - A pilot study to explore the safety of pyridostigmine in palliative care patients already prescribed laxatives receiving medications that deliver an anticholinergic load and proven retention of more than 5 radiopaque markers
  • A radmonised double-blind multi-site parallel arm controlled trial to assess relief of refractory breathlessness comparing fixed doses of morphine, oxycodone and placebo - A radmonised double-blind multi-site parallel arm controlled trial to assess relief of refractory breathlessness comparing fixed doses of morphine, oxycodone and placebo.
  • A randomised double blind dose non-inferiority trial of aspirin in Lynch syndrome. CaPP3 - A randomised double blind dose non-inferiority trial of a daily dose of 600mg versus 300mg of enteric coated aspirin as a cancer preventive in carriers of a germline pathological mismatch repair gene defect, Lynch Syndrome. Project 3 in the Cancer Prevention Programme (CaPP3)
  • A randomised trial of Telehealth intervention for patient’s post-HSCT - A randomised trial of a telehealth programme of combined physical and psychological training in patients following Hematopoietic Stem Cell Transplant (HSCT)
  • A randomized clinical trial comparing effectiveness of 4RIF and 9INH for treatment of latent TB infection - A randomised controlled trial comparing 9 months Isoniazid (INH) to 4 months Rifampicin (RIF) as therapy for latent TB infection
  • A Randomized Controlled Trial of Photodynamic Therapy vs Radiotherapy for Superficial Skin Cancer - A Randomized Controlled Trial of Photodynamic Therapy vs Radiotherapy for Superficial Skin Cancer
  • A randomized, double-blind, multi-site, parallel arm controlled trail to assess relief of refractory breathlessness comparing oral sertraline and placebo. - A randomized, double-blind, multi-site, parallel arm controlled trail to assess relief of refractory breathlessness comparing oral sertraline and placebo.
  • A Randomized, Open-label, Phase 3 Study in subjects with Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in combination with Dexamethasone, Comparing Once-weekly versus Twice-weekly Car - A Randomized, Open-label, Phase 3 Study in subjects with Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in combination with Dexamethasone, Comparing Once-weekly versus Twice-weekly Carfilzomib Dosing (A.R.R.O.W.)
  • A Study of MGA012 in Patients with Advanced Solid Tumors - A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors
  • A three arm randomized, open-label Phase II study of radium-223 dichloride 50 kBq/kg versus 80 kBq/kg, and versus 50 kBq/kg in an extended dosing schedule in subjects with castration-resistant prostat - A three arm randomized, open-label Phase II study of radium-223 dichloride 50 kBq/kg versus 80 kBq/kg, and versus 50 kBq/kg in an extended dosing schedule in subjects with castration-resistant prostate cancer metastatic to the bone
  • A1481324 - A1481324 A multinational, multicentre study to assess the effects of oral Sildenafil on mortality in adults with Pulmonary Arterial Hypertension (PAH)
  • AbbVie AD M15-566 - Clinical Study Protocol M15-566 - A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimer's Disease.
  • ABBVIE M13-576 - A Follow-up Study to Assess Resistance and Durability of Response to Abbvie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection.
  • ABC - Anti-P D 1 Brain Collaboration Study - A phase II study of nivolumab and nivolumab combined with ipilimumab in patients with melanoma brain metastases
  • ABI-007-PANC-003 - A Phase 3, Multi-centre, Open-label, Randomized Study of nab®-Paclitaxel Plus Gemcitabine versus Gemcitabine alone as Adjuvant Therapy in subjects with Surgically Resected Pancreatic Adenocarcinoma
  • ABI-1968-201: Study of Topical ABI-1968 in Subjects with aHSIL - ABI-1968-201: Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Topical ABI-1968 in Subjects with Anal High-Grade Squamous Intraepithelial Lesions (aHSIL)
  • ACE-CL-006 - A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia (ACE-CL-006)
  • ACE-CL-007 - A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia (ACE-CL-007)
  • ACED - A Phase II randomised placebo-controlled, double blind, multisite study of Acetazolamide versus placebo for management of cerebral oedema in recurrent and/or progressive High Grade Glioma requiring treatment with Dexamethasone
  • aCRT Study - Adaptive Cardiac Resynchronization Therapy (aCRT) Study
  • AdaptHIV - A Randomised Controlled Trial (RCT) of AdaptHIV, an internet Cognitive Behavioural Therapy (iCBT) program for the treatment of depression and anxiety in men who have sex with men (MSM) who are living with HIV
  • AdaptResponse - AdaptResponse Study
  • ADAURA - A Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy
  • ADRENAL - ADjunctive coRticosteroid trEatment iN criticAlly ilL patients - A randomised blinded placebo controlled trial of hydrocortisone in critically ill patients with septic shock - ADRENAL
  • ADVICE - Attenuation of D-dimer using Vorapaxar to target Inflammatory and Coagulation Endpoints. A double blind randomised comparison of vorapaxar versus placebo for the treatment of HIV associated Inflammation and coagulopathy in patients with well controlled HIV replication.
  • AGOC - A randomised phase III double-blind placebo-controlled study of regorafenib in refractory Advanced Gastro-oesophageal Cancer
  • AHOD/DAD/RESPOND - The Australian HIV Observational Database
  • AI438047/205888 - A Multi-arm, Phase 3, Randomised, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of BMS-663068/GSK3684934 in Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant HIV-1
  • AK 104-101 - A Phase 1a/b multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, and anti-tumor activity of AK 104 in subjects with advanced solid tumors.
  • Alectinib versus crizotinib in treatment-naive ALK Positive advanced non-small cell lung cancer - ALEX study - Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib In Treatment-Naïve Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
  • ALLG MDS4; AZA v LEN AZA in MDS - A Randomised Phase II study comparing the efficacy of 5azacitidine alone versus combination therapy with lenalidomide and 5azacitidine in patients with higher risk myelodysplastic syndromes (MDS) and low marrow blast count acute myeloid leukaemia (AML).
  • ALLG MM11 - A phase 3, multicentre, randomised, controlled study to determine the efficacy and safety of cyclophosphamide,lenalidomide and dexamethasone (CRD) versus melphalan (200mg/m2) followed by stem cell transplantation in newly diagnosed multiple myeloma subjects.
  • ALLG MM19 - A Phase 3 trial of thalidomide-dexamethasone consolidation versus thalidomide-dexamethasone-Ixazomib consolidation for transplant eligible multiple myeloma patients undergoing a single ASCT as part of front-line therapy
  • ALX0171-C204 - A randomized, double-blind, multicenter study to evaluate the efficacy and safety of ALX 0171 versus placebo, in addition to standard of care, in adults who have undergone hematopoietic stem cell transplantation and present with a respiratory syncytial virus respiratory tract infection
  • ALX0681-C301 - A Phase III Double-Blind, Randomized, Parallel Group, Multicenter Placebo-Controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura
  • AM0010-301 - A Randomised Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen
  • AMC-095 - Phase I study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an expansion Cohort in HIV Associated Solid Tumors.
  • Amgen 20160275 - A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
  • AMRMRI15 - Validation of a novel MRI protocol for detection of amyloid brain burden in Alzheimer’s disease: A pilot study.
  • An Extended Access Program To Assess Long Term Safety Of Bardoxolone Methyl - Ranger - An Extended Access Program To Assess Long Term Safety Of Bardoxolone Methyl In Patients With Pulmonary Hypertension
  • An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma - An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma
  • An open label, multi-center, Phase IV roll-over protocol for patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study and are judged by the investigator to be - An open label, multi-center, Phase IV roll-over protocol for patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study and are judged by the investigator to benefit from continued treatment
  • Anavex - A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-week Safety and Efficacy trial of ANAVEX2-73 for the Treatment of Early Alzheimer’s Disease (AD)
  • ANTIVA - Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Topical ABI-1968 in Subjects with Anal High-Grade Squamous Intraepithelial Lesions (aHSIL)
  • APD811-007 - An Open-Label Extension Study of APD811-003 in Patients with Pulmonary Arterial Hypertension
  • APML5: bioavailability of oral arsenic trioxide in consolidation therapy for APL - A phase I pharmacokinetic evaluation of oral arsenic trioxide in previously untreated patients with acute promyelocytic leukaemia
  • ARCHIVE - Age-related clonal haematopoiesis in an HIV evaluation cohort (ARCHIVE): a follow-on study of the Australian Positive & Peers Longevity Evaluation Study
  • AREISSA - Altering the rehabilitation environment to improve stroke survivor activity (AREISSA): a phase II trial.
  • ASCOLT - Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers. An International, Multi-centre, Double Blind, Randomised Placebo Controlled Phase III Trial.
  • ASSIST-CLAD Study - ASSIST – CLAD study
  • AURA3 - A Phase III, Open Label, Randomized Study of AZD9291 versus Platinum-Based Doublet Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours harbour a T790M mutation within the Epidermal Growth Factor Receptor Gene
  • BAY 94-9343 / 15834 - Phase 1b multi-indication study of anetumab ravtansine (BAY 94-9343) in patients with mesothelin expressing advanced or recurrent malignancies
  • BBI608-336 brighter - A Phase III Randomized, Double-Blind, Placebo-Controlled Clinical Trial of BBI608 Plus Weekly Paclitaxel Vs. Placebo Plus Weekly Paclitaxel In Adult Patients with Advanced, Previously Treated Gastric and Gastro-Esophageal Junction (GEJ) Adenocarcinoma
  • BEAMS - A pragmatic, phase III, multi-site, double-blind, placebo controlled, parallel arm, dose increment randomised trial of regular, low dose extended release morphine for chronic refractory breathlessness.
  • BGB-290-103 - A Phase 1b study to assess the safety, tolerability and clinical activity of BGB-290 in combination with temozolomide (TMZ) in subjects with locally advanced or metastatic solid tumors
  • Biogen BIIBO37 - A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease.
  • BLAM - A phase IIb study of Blinatumomab + Cytarabine (AraC) and Methotrexate in adult B-precursor Acute Lymphoblastic Leukaemia - BLAM - A phase IIb study of Blinatumomab + Cytarabine (AraC) and Methotrexate in adult B-precursor Acute Lymphoblastic Leukaemia
  • BLING II - A phase III randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients.
  • BOSTON: Bortezomib, Selinexor, and Dexamethasone in Patients with Multiple Myeloma - A Phase 3 Randomized, Controlled, Open-Label Study of Selinexor, Bortezomib, and Dexamethasone (SVD) Versus Bortezomib and Dexamethasone (VD) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM).
  • CA017-003 - A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclocal Antibody) in Advanced Malignant Tumors
  • CAMERA - Combination Antibiotic treatment for Methicillin Resistant Staphylococcus aureus
  • CAMERA2 - CAMERA 2 Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus infection – An investigator-initiated, multicentre, parallel group, open labelled randomised controlled trial.
  • CanStem303C (aka BB608-303CRC) - A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC).
  • Cardiac MR in Cardiac Transplant Rejection - Randomised Safety Outcomes Study Comparing Patients Diagnosed and Treated for Acute Cardiac Rejection on Cardiac MRI Compared to Endomyocardial Biopsy
  • CATALYST - A study of the efficacy and safety of Bardoxolone methyl in patients with connective tissue disease-associated pulmonary arterial hypertension.
  • CC-90001-CP-003 - A Phase 1b, Multicenter, Open-Label, Staggered-Dose Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Doses Of Cc-90001 For 12 Weeks In Subjects With Pulmonary Fibrosis
  • CC-90001-IPF-001 - A Phase 2, 24-Week Randomized, Double-blind, Placebo-Controlled Multicenter Study, Followed by a 28-Week Treatment Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects with Idiopathic Pulmonary Fibrosis
  • CEASE/ISTEP - Control and Eradication within Australia of Hepatitis C from people living with HIV (Surveillance Phase).
  • CELESTIAL - To evaluate the effect of Cabozantinib compared with placebo on overall survival in subjects with advanced HCC previously treated with Sorafenib.
  • Checkmate 651 CA209-651 - An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  • CheckMate 9ER: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9ER - A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma (CA209-9ER).
  • Chronos 4 - A Phase III, randomized, double-blind, controlled, multicentre study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed incident non-Hodgkin’s lymphoma (iNHL)
  • CINC424D2301 - REACH 3 - A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs host disease after allogenic stem cell transplantation (REACH 3)
  • CL3­-95005-­004 - An open-label early access phase IIIb study of trifluridine / tipiracil (S 95005/TAS-102) in patients with a pretreated metastatic colorectal cancer
  • Clinical Trial Evaluation of the Percutaneous 4TECH TriCinch Coil Tricuspid Valve Repair - Clinical Trial Evaluation of the Percutaneous 4TECH TriCinch Coil Tricuspid Valve Repair
  • COG RX 2 - A randomized, double-blind, placebo-controlled, parallel-group, phase 2 Study to evaluate the safety and efficacy of ct1812 in subjects with mild to moderate Alzheimer’s disease
  • CogRX- phase 1 - A double-blind, placebo-controlled, phase I study of the safety and pharmacokinetics of two doses of ct1812 in subjects with mild to moderate alzheimer’s disease.
  • CombiRT - RT & combi in metastatic melanoma - An open-label, single-arm, phase I/II, multicentre study to evaluate the safety and efficacy of the combination of dabrafenib, trametinib and palliative radiotherapy in patients with unresectable (stage IIIc) and metastatic (stage IV) BRAF V600E/K mutation-positive cutaneous melanoma (ANZMTG 02.14)
  • Confocal EndoMicroscopy Optimisation Research-HIV/IBD - Confocal EndoMicroscopy Optimisation Research-HIV and IBD (CEMOR-HIV/IBD) study
  • Controlled trial of a decision aid for ulcerative colitis patients: enhancing patient's quality of life, empowerment, quality decision making and disease control. - Controlled trial of a decision aid for ulcerative colitis patients: enhancing patient's quality of life, empowerment, quality decision making and disease control.
  • CP-MGA271-03 - A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination with Pembrolizumab in Patients with Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers
  • CP-MGD009-01 - A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Patients with Unresectable or Metastatic B7-H3-Expressing Neoplasms and Neoplasms whose Vasculature Expresses B7-H3
  • CRUSADES - Charcot Foot Quantitative Ultrasound and Denosumab Study
  • CS1003-101 - A Phase Ia/Ib, Open-Label, Multi-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects with Advanced Solid Tumors
  • D3FEAT - A phase IV open-label, multicentre, international trial of paritaprevir/ritonavir, ombitasvir, dasabuvir and ribavirin for people with chronic hepatitis C virus genotype 1 infection and recent injection drug use or receiving opiate substitution therapy
  • D4190C00006 - A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-small Cell Lung Cancer
  • DARE - C - II - Directly-acting antiviral (DAA) based therapy for recently acquired Hepatitis C II.
  • DARLO-C - Scale-up of treatment for hepatitis C infection among people who inject drugs: A phase IV, open-label, single arm, multicentre trial of elbasvir/grazoprevir for genotype 1 or 4 in people with chronic hepatitis C virus infection and recent injecting drug use.
  • De-labelling patients with antibiotic allergy in Sydney adult and paediatric hospital allergy services-towards standardisation and improved patient outcomes - De-labelling patients with antibiotic allergy in Sydney adult and paediatric hospital allergy services-towards standardisation and improved patient outcomes
  • DETECT trial - Radioguided Surgery With Technetium99m-labelled PSMA To Aid Intra-operative Lymph Node Metastases Detection For Patients Undergoing RARP For Prostate Cancer
  • Determination of febuxostat plasma concentrations by HPLC with fluorescence-detection in healthy subjects - Determination of febuxostat plasma concentrations by HPLC with fluorescence-detection in healthy subjects
  • Diabetes and writing study - Internet-based benefit finding writing for adults with diabetes: Feasibility testing and a randomised controlled trial
  • Dose Optimization Study of Idelalisib in Follicular Lymphoma (GS-US-313-1580) - Dose Optimization Study of Idelalisib in Follicular Lymphoma (GS-US-313-1580)
  • DUOGLOBE - DUOdopa/Duopa in Patients with Advanced Parkinson's Disease (PD) –a GLobal OBservational Study Evaluating Long-Term Effectiveness.
  • ECHELON - 2 - A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas.
  • Echocardiographic and haemodynamic assessment of LVAD patients - Short and long-term changes in left ventricular function in patients with left ventricular assist device: echocardiographic and invasive haemodynamic assessment
  • Efficacy and safety of SAR156597 in the treatment of Idiopathic Pulmonary Fibrosis (IPF): A randomized, double-blind, placebo-controlled, 52-week dose ranging study (ESTAIR) - Efficacy and safety of SAR156597 in the treatment of Idiopathic Pulmonary Fibrosis (IPF): A randomized, double-blind, placebo-controlled, 52-week dose ranging study (ESTAIR)
  • EISAI - A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease
  • EMR 200104011 - AR_Open-label, single-arm, phase IV, multicenter trial to explore the immunogenicity of the liquid formulation of Saizen® in subjects with growth hormone deficiency (GHD) of adult onset.
  • ENGAGE PWS - The effects of a new GLP-1 agonist on appetite and gastric emptying in Prader-Willi syndrome
  • ENZAMET Trial - A randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer
  • ENZARAD Trial - A randomised phase 3 trial of enzalutamide in androgen deprivation therapy for high risk, clinically localised, prostate cancer.
  • EPIC - Impact of the rapid expansion of pre-exposure prophylaxis (PrEP) on HIV incidence, in a setting with high HIV testing and antiretroviral treatment coverage, to achieve the virtual elimination of HIV transmission by 2020: a NSW HIV Strategy implementation project.
  • Erythropoietin in Traumatic Brain Injury EPO-TBI - A randomised, placebo-controlled trial of erythropoietin in ICU patients with traumatic brain injury.Erythropoietin in Traumatic Brain Injury EPO-TBI
  • Evaluation of Radium-223 in combination with Abiraterone in CRPC - ERA 223 (Radium lll) - A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)
  • Evolut R Low Risk - Transcatheter Aortic Valve Replacement (TAVR) with the Medtronic Transcatheter Aortic Valve Replacement System (TAVR) in Patients at Low Risk for Surgical Aortic Valve Replacement (SAVR) EvolutR low risk study
  • ExPAH - The effect of an outpatient exercise training program on haemodynamic and cardiac magnetic resonance parameters of right ventricular function in patients with pulmonary arterial hypertension.
  • ExPAH - Optional - Optional adjunct study to the ExPAH study - investigating dynamic right heart haemodynamic via exercise during right heart catheter procedure
  • Expanded PrEP Implementation in Communities in NSW (EPIC-NSW) - Impact of the rapid expansion of pre-exposure prophylaxis (PrEP) on HIV incidence, in a setting with high testing and ART coverage, to achieve the virtual elimination of HIV transmission by 2020: a NSW HIV Strategy Implementation Project.
  • EXPEDITION-2 - Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus (HCV) Genotype 1 – 6 Infection and Human Immunodeficiency Virus-1 (HIV-1) Co-Infection (EXPEDITION-2)
  • EXPERT: EXamining PErsonalised Radiation Therapy for low-risk early breast cancer. - ANZ 1601/BIG 1602/ EXPERT: A randomised phase III trial of adjuvant radiation therapy versus observation following breast conserving surgery and endocrine therapy in patients with molecularly characterised luminal A early breast cancer
  • EXTEND - Extending the time for Thrombolysis in Emergency Neurological Deficits
  • FACTS - F actor concentrates versus A llogeneic blood products in bleed - A Randomised,single centre trial comparing the use of factor concentrates versus fractionated,allogeneic blood products using treatment algorithms based on point of care whole blood viscoelastic tests/platelet function tests in patients bleeding post cardiac surgery
  • FANTOM II Trial - Safety and Performance Study of the FANTOM Sirolumus-eluting bioresorbable coronary scaffold
  • FGCL-4592-082 - A Phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (MDS) with Low Red Blood Cell (RBC) Transfusion Burden (LTB)
  • FIB audit - Patients with fractured neck of femur- pain assessment and management surgical and non-surgical from 0-72 hours
  • FILGOTINUB - Combined Phase 3, Double Blind, randomized, Placebo-Controlled Studies evaluating the Efficacy and Safety of Filgotinib in the induction and maintenance of remission subjects with moderately to severely active Crohn’s Disease.
  • FLU PLUS 003 - An International Observational Study to Characterize Adults Who Are Hospitalized with Influenza or Other Targeted Respiratory Viruses (MERS-CoV & SARS-CoV)
  • GALACTIC HF - A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction.
  • GALACTIC-HF STUDY - A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction.
  • GB28547 - A Phase II Randomized double blind placebo controlled study to assess the efficacy and safety of lebrikizumab in patients with idiopathic pulmonary fibrosis
  • GEMINI 1 204861 - Phase 3 Randomised double blind, multicentre, parallel group, non inferiority study evaluating the safety, efficacy and tolerability of Dolutegravir and Lamivudine compared to Dolutegravir plus Tenofovir Lemtricitabine in HIV-1 infected treatment naïve adults.
  • Generation 1 - A randomized, double-blind, placebo-controlled, two-cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's disease
  • Generation 2 - A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s Disease (AD)
  • GENETECH - A phase ii, multicentre, randomized, double-blind, placebo-controlled, Parallel-group, efficacy, and safety study of mtau9937a in patients with prodromal to mild Alzheimer’s disease
  • GENOMICS (Flu 004) - Influenza Genomics Study-A substudy of qualifying INSIGHT FLU studies
  • Gilead 0115 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia
  • GO28888 LORELEI - A Phase Ii Randomized, Double-Blind Study Of Neoadjuvant Letrozole Plus Gdc-0032 Versus Letrozole Plus Placebo In Postmenopausal Women With Er-Positive/Her2-Negative, Early Stage Breast Cancer
  • GO29438 - Phase III Open-Label Randomised Study of Atezolizumab in Combination with Carboplatin or Cisplatin+Pemetrexed Compared with Carboplatin or Cisplatin+Pemetrexed in Patients who are Chemotherapy Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer
  • GO29689 - A Phase Ii, Open-Label, Randomized Study Of Gdc-0810 Versus Fulvestrant In Postmenopausal Women With Advanced Or Metastatic Er + /Her2 − Breast Cancer Resistant To Aromatase Inhibitor Therapy
  • GO30103 - A Phase Ia/Ib Open-Label, Dose Escalation Study Of The Safety And Pharmacokinetics Of Mtig7192a As A Single Agent And In Combination With Atezolizumab In Patients With Locally Advanced Or Metastatic Tumors
  • GO39932 - A Phase Ia/Ib, Multicenter, Open-Label, Dose Escalation, Dose Expansion Study Evaluating The Safety, Pharmacokinetics, And Activity Of GDC-9545 Alone Or In Combination With Palbociclib And/Or Lhrh Agonist In Patients With Locally Advanced Or Metastatic Estrogen Receptor−Positive Breast Cancer
  • GRAVITAS-301 - A Randomized, Double Blind, Placebo Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First Line Acute Graft-Versus-Host Disease
  • GRIPHON OL: Prostacyclin (PG12) Receptor agonist in pulmonary arterial - Long-term single-arm open-label study to assess the safety and tolerability of Selexipag (ACT-293987) in patients with pulmonary arterial hypertension
  • GSK 205888 (BMS-AI428-047) - A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of BMS-663068/GSK3684934 in Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant HIV-1
  • GS-US-296-1080 - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS 5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma - country
  • GS-US-380-1844 - A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed.
  • GS-US-380-1878 - A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boosted Atazanavir or darunavir plus either Emtricitabine/Tenofovir or Abacavir/Lamivudine to GS-9883/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults .
  • GS-US-384-1943 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
  • GS-US-384-1944 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)
  • GS-US-418-3898 - GS-US-418-3898 Combined Phase 2b/3, Double- Blind, Randomized. Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Ulcerative Colitis
  • GS-US-418-3899 - GS-US-418-3899 A Long Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis
  • GS-US-419-3895 - GS-US-419-3895 Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease
  • GS-US-419-3896 - GS-US-419-3896 A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease
  • GTi1201- VIC/NSW/QLD_SSA - A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1 Proteinase Inhibitor (Human) in Subjects with Pulmonary Emphysema due to Alpha1 Antitrypsin Deficiency
  • GTx Protocol Number: G200802 - A Phase 2 Open Label, MultiCenter, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx024 on Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women
  • HALO-109-301 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Milticenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma.
  • HANMI NSCLC - A single-arm, open-label, Phase 2 study evaluating the efficacy, safety and pharmacokinetics of HM61713 in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor
  • Haplo transplant with PTCy - A phase II trial of haploidentical peripheral blood stem cell transplantation with post- transplant cyclophosphamide as GVHD prophylaxis.
  • HI-C - HIV and Immunity Cancer cohort study. A non-interventional biobanking study - Kirby.
  • High-flow nasal cannula versus low-flow nasal cannula oxygenation in lung transplant patients undergoing diagnostic transbronchial biopsy: A randomised controlled trial - High-flow nasal cannula versus low-flow nasal cannula oxygenation in lung transplant patients undergoing diagnostic transbronchial biopsy: A randomised controlled trial
  • HIV Latency - The identification and quantification of HIV CNS latency biomarkers.
  • HIV SCT - Blood and tissue collection of patients with HIV-1 infection undergoing allogeneic haematopoietic stem cell transplantation.
  • HS110201 - Phase 2, Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Viagenpumatucel-L (HS110) in Combination with Low Dose (Metronomic) Cyclophosphamide Versus Chemotherapy Alone in Patients with Non-Small Cell Lung Adenocarcinoma after Failure of Two or Three Previous Treatment Regimens for Advanced Disease
  • HSCT for Auto-Immune Diseases - A Single Centre Phase II Study of Haematopoietic Stem Cell Transplantation For Severe Auto-Immune Diseases
  • I3Y-MC-JPCJ - An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination with Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma
  • I8S-MC-JUAB - A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996)Administered Alone or in Combination with Other Agents in Advanced Cancer
  • I8X-MC-JECA - A Phase 1 Study of LY3200882 in Patients with Solid Tumors
  • iCanADAPT RCT - A Randomised controlled Trial (RCT) of iCanADAPT, an internet Cognative Behavioural Therapy (iCBT) programe for the treatment of depression and anxiety in early-stage cancer patients and cancer survivors
  • iCHIP - Effect of Immune Checkpoint Inhibitors on HIV Persistence: An observational study among HIV patients with cancer
  • ICURE - A multinational, multi-centre, randomized, double-blind, active comparator, phase III clinical trial to evaluate the efficacy and safety of donepezil transdermal patch in patients with Alzheimer’s disease
  • IMCgp-100-202 - A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator’s Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma
  • INCB 39110-230 - An Open-Label, Multiple Simon 2-Stage Study of INCB03911 Administered Orally to Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera-Myelofibrosis (PPVMF) or Post Essential Thrombocythemia-Myelofibrosis (PET-MF)
  • INCB 50465-202 - A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
  • INOvation-1 - A Phase 3, Placebo Controlled, Double-blind, Randomized, Clinical Study to Determine Efficacy, Safety and Tolerability of Pulsed, Inhaled Nitric Oxide (iNO) versus Placebo in Symptomatic Subjects with Pulmonary Arterial Hypertension (PAH): INOvation-1 (Part 1 and Part 2)
  • InTENSE - The InTense Trial: optimising upper limb recovery following stroke.
  • INTERHEART - Diagnostic and Therapeutic Application of Microarrays in Heart Transplantation, a Multicenter Study.
  • International Revalving Registry. Percutaneous Aortic Valve Replacement (PAVR) with the Corevalve Revalving System - International Revalving Registry. Percutaneous Aortic Valve Replacement (PAVR) with the Corevalve Revalving System
  • ITACS - IV Iron for Treatment of Anaemia before Cardiac Surgery
  • Janssen - EARLY - A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects who are Asymptomatic At Risk for Developing Alzheimer’s Dementia.
  • JPCF - MonarchE: Protocol I3Y-MC-JPCF A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
  • KCP-330-009: A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - KCP-330-009: A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
  • KEYNOTE-365 - Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • LIMA - A randomised double blind placebo controlled study of lisdexamfetamine for the treatment of methamphetamine dependence
  • Long Term Non-Progression Study - Long-Term non-progression in people with HIV Infection
  • LUPIN trial - Radionuclide therapy using 177Lu-PSMA: a phase I study in men with castrate-resistant prostate cancer to determine the clinical benefit of combination therapy with idronoxil
  • LuPSMA Trial - Radionuclide therapy using 177Lu-PSMA: a pilot study in men with castrate-resistant prostate cancer
  • M14-423 - Protocol M14-423: An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)
  • M15-654: A Phase 1/2, Multicenter, Open-Label Dose-Escalation and Blinded Expansion Study of Venetoclax, Daratumumab and Dexamethasone Combination Therapy in Subjects with Relapsed or Refractory Multi - A Phase 1/2, Multicenter, Open-Label Dose-Escalation and Blinded Expansion Study of Venetoclax, Daratumumab and Dexamethasone Combination Therapy in Subjects with Relapsed or Refractory Multiple Myeloma
  • MAGNIFI Trial - Metastasis assessment with Gallium-68 PSMA and Nanoparticle Imaging Fusion International
  • Mapping Reservoir - HIV infected patient on successful suppressive antiviral therapy blood collection.
  • Mapping Study - Integrating NSW/ACT healthcare for stroke and hip fracture - Mapping the relationship between the availability of outpatient services and inpatient rehabilitation length of stay in NSW/ACT hospitals.
  • Maxigesic RCT - A RCT of Paracetamol, Ibuprofen and their combination in the outpatient treatment of acute moderate to severe musculoskeletal pain within the first five days of its onset
  • MDV3800 06 - A Phase 2, Open-Label, 2-Arm, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone)
  • Medicinal Cannabis for anorexia in advanced cancer - Phase II, dose ranging study of the pharmacokinetics dose-response parameters, and feasibility of vaporised botanical leaf cannabis
  • Megestrol, dexamethasone and placebo for anorexia - Randomised, double blind control trial of megestrol acetate, dexamethasone and placebo in the management of anorexia in patients with cancer
  • Memory B-Cell/HBV - Determining the unique processes that control memory B cell-mediated secondary antibody responses
  • Metformin in heart failure - The safety and pharmacokinetics of metformin in heart failure
  • MK-5172 in Combination with MK-8742 in Subjects on Opiate Substitution Therapy - A Phase III, Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naive Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection who are on Opiate Substitution Therapy.
  • MoST substudies 6-8: Olaparib plus Durvalumab - Molecular Screening and Therapeutics (MoST) Program Substudies 6 – 8: Single arm, open label, signal seeking, phase IIa trial of the activity of Olaparib in combination with Durvalumab in patients with tumours with homologous recombination repair defects
  • MoST Substudy 1 - Palbociclib for cancer - Molecular Screening and Therapeutics (MoST) Program Substudy 1 – Single arm, open label, signal seeking, phase Ib/IIa trial of the CDK4/6 inhibitor palbociclib in patients with tumours with amplified D‐type cyclins or CDK4 or inactivation of CDKN2A.
  • MoST Substudy 2-5: Durva plus Treme - Molecular Screening and Therapeutics (MoST) Program Substudies 2 – 5: Single arm, open label, signal seeking, phase IIa trial of the activity of Durvalumab (MEDI4736) in combination with Tremelimumab in patients with advanced rare or neglected cancers
  • MVT-601-3201 - A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer
  • My Medic Watch - An Observational Single Blind Study of a Smartwatch App for the Detection of Falls in an at-risk population.
  • NABNEC - A Randomised Phase II Study Of nab-paclitaxel In Combination with Carboplatin as First Line Treatment of Gastrointestinal Neuroendocrine Carcinomas
  • Neo Trio - A Phase II, Randomised, Open Label Study of Neoadjuvant Dabrafenib, Trametinib and / or Pembrolizumab in BRAF V600 Mutant Resectable Stage IIIB/C Melanoma
  • Nohla Study - Eastern Seaboard Application - A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Dose-Finding Study of NLA101 in Adults Receiving High Dose Chemotherapy for Acute Myeloid Leukemia
  • NVX-108-GBM1B - NVX-108-GBM1B: A phase 1b/2 dose-finding, pharmacokinetic and pharmacodynamic study of NVX-108 combined with radiation and temozolomide in patients with newly-diagnosed glioblastoma multiforme
  • ODM-201 in addition to standard androgen deprivation therapy (ADT) and docetaxel in metastatic hormone-sensitive prostate cancer Acronym: ARASENS - A randomized, double–blind, placebo–controlled Phase III study of ODM–201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone–sensitive prostate cancer.
  • Onconova 04-30 - A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physicians Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent
  • Online and Phone Assistance for Lung-cancer (OPAL) - A randomised controlled trial of online versus telephone-based information and support: Can electronic platforms deliver effective care for lung cancer patients?
  • ONTRANS - The Effect of Oral Nicotinamide on Non-Melanoma Skin Cancer Incidence and Actinic Keratoses in Renal, Hepatic, Heart and Lung Transplant Recipients: A Randomised Controlled Trial
  • OPAL - The first placebo controlled trial of opioid analgesia for acute spinal pain
  • Oscillate - Phase 2 trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation positive advanced non-small cell lung cancer.
  • OXYGEN-HF - Oxygen to relieve dyspnoea in non-hypoxaemic patients with end-stage heart failure
  • OZI 202 - A Long Term Follow-up Protocol to evaluate the safety and survival of autologous CD34+ hematopoietic progenitor cells transduced with an anti-HIV-1 ribozyme (OZ1) in patients with HIV-1 infection
  • PanCO - An open label, single arm pilot study of OncoSil™, administered to study participants with unresectable locally advanced pancreatic adenocarcinoma, given in combination with FOLFIRINOX or gemcitabine+nab-paclitaxel chemotherapies.
  • PATINA (AFT–38 / ANZ 1701) - A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
  • PAX-1 - A Randomised, Double-Blind, Parallel-Group, Placebo Controlled Phase II Study to Assess the Clinical Benefit of 3 Doses of PAX-1 as Adjunctive Treatment for Persistent Cancer Pain
  • PCI32765DBL3001 (Phoenix) CRGH - A Randomised, Double blind, Placebo controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI32765 (Ibrutinib), in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Subjects with Newly Diagnosed NonGerminal Center BCell Subtype of Diffuse Large BCell Lymphoma
  • PCI-32765LYM1002 - A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Combination of Ibrutinib with Nivolumab in Subjects with Haematologic Malignancies
  • PCYC-1140-IM - A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination with Corticosteroids versus Placebo in Combination with Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD).
  • Perinatal 'MUMentum' Program - A randomised controlled trial comparing the clinical efficacy of internet-delivered cognitive behavioural therapy for perinatal anxiety and depression to treatment as usual: Perinatal 'MUMentum' Program
  • PHAEDRA - Unable to find file on Common Drive or Hardcopy file.
  • Phase I Study of MK-3475 in Combination with Trametinib and Dabrafenib - A Phase I/II Study to Assess the Safety and Efficacy of MK-3475 in Combination with Trametinib and Dabrafenib in Subjects with Advanced Melanoma
  • Phase III RCT of melatonin for prevention of delirium in cancer - Randomised double-blind placebo-controlled phase III trial of oral melatonin for the prevention of delirium in hospital in people with advanced cancer
  • PILLAR : TMC435-TiDP16 - A Phase IIb, randomised, double-blind, placebo-controlled trial to investigate the efficacy, tolerability, safety and pharmacokinetics of TMC435 as part of a treatment regimen including PegIFN alfa-2a & Ribavirin in treatment naive genotype 1 Chronic Hepatitis C infected subjects.
  • POH035-13 - A Randomized, Double-Blind, Placebo Controlled, Crossover, Phase IIa Study Comparing a Single Application TPM®/Oxycodone Patch versus Vehicle Patch in the Topical Treatment of Patients with Postherpetic Neuralgia (POH035-13).
  • Polymer-Free DES Trial - A Clinical Evaluation of the Medtronic Polymer-Free Drug-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions
  • Post-Operative Skin Trial (POST Study) - Post-Operative Concurrent Chemo-Radiotherapy versus Post-Operative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck
  • PRELUDE - Implementation of HIV pre-exposure prophylaxis with antiretroviral medications among people at high risk for HIV infection: A demonstration project
  • PReSS - A retrospective cohort study of the newly implemented Rehab PRESS screening service (whereby all hospital admissions are proactively screened for rehab needs 5-7 days after admission)
  • PRIME-MIC-1 - Identification of plasma biomarkers of therapeutic response in men with metastatic prostate cancer
  • Protocol 401 - A Phase 1 Study of ES414 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Protocol I7X-MC-LLCF - Effect of LY3202626 on Alzheimer’s Disease Progression as Measured by Cerebral 18F-AV-1451 Tau-PET in Mild Alzheimer’s Disease Dementia.
  • Protocol TDE-PH - 310 - A Phase III, International, Multi-Center, Randomized, Double- Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects with Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
  • Protocol TDE-PH - 311 - An Open-Label Extension Study of UT-15C in Subjects with Pulmonary Arterial Hypertension - A Long-Term Follow-Up to Protocol TDE-PH-310.
  • Proton Pump Inhibitors vs. Histamine-2 Receptor Blockers for Ulcer Pro - A multi-centre, cluster randomised, crossover, registry trial comparing the safety and efficacy of proton pump inhibitors with histamine-2 receptor blockers for ulcer prophylaxis in intensive care patients requiring invasive mechanical intervention
  • PULS - Prevalence of post-stroke upper limb spasticity and associated problems in nursing home residents; a cross-sectional study
  • QUALITY - QUAlity of adherence to guideline recommendations for Life-saving treatment in heart failure: an international survey.
  • Quality of recovery after propofol vs sevoflurane anaesthesia: A randomised study in lumbar spinal surgery patients - Quality of recovery after propofol vs sevoflurane anaesthesia: A randomised study in lumbar spinal surgery patients
  • RADICAL - RADiotherapy or Imiquimod in Complex lentigo mALigna - A randomised controlled multicentre trial of imiquimod versus radiotherapy for lentigo maligna (LM) when staged surgical excision with 5mm margins is not possible, is refused, or fails (ANZMTG 02.12)
  • RAD-TAC - Everolimus for the prevention of CNI-induced left ventricular hypertrophy in heart transplantation.
  • Rapid HIV testing evaluation framework - Rapid HIV testing evaluation framework
  • REACH-C - Real world Efficacy of Antiviral therapy in Chronic Hepatitis C.
  • REACT - A randomised study of interferon-free treatment for recently acquired hepatitis C in people who inject drugs and people with HIV Coinfection.
  • Reboot Online - Reboot Online: A pilot trial and randomised controlled trial of an online treatment program for chronic pain
  • REDUCE LAP-HF RANDOMIZED TRIAL II - A study to evaluate the Corvia Medical, Inc. IASD® System II to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure
  • REDUCE LAP-HFREF Trial - A study to evaluate the Corvia Medical, Inc. IASD System II to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure with Reduced Ejection Fraction.
  • Reducing the impact of aphasia in stroke patients and their caregivers - Reducing the impact of aphasia in stroke patients and their caregivers a year post onset via a brief early intervention: a cluster randomised control trial of the Action Success Knowledge (ASK) program.
  • RESPECT-ESUS - Randomized,doubleblind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110mg or 150mg, oral b.d) versus acetylsalicylic acid (100mg oral q.d) in patients with Embolic Stroke of Undetermined Source
  • RESTORE II Trial - Safety and Performance Study of the ReZolve2 Sirolimus-Eluting Bioresorbable Coronary Scaffold. A prospective, multi-centre, Safety and Performance study.
  • ROCHE AD - A PHASE III, Multicentre , randomized, Double Blind, Placebo-controlled, parallel-group, Efficacy and Safety study of Crenezumab in patients with prodromal to mild Alzheimers Disease.
  • ROCHE CREAD 2 OL - A multicentre, open-label, long-term extension of phase iii studies (bn29552/bn29553) of crenezumab in patients with Alzheimer’s disease
  • ROCHE GRADUATE - A phase III, multicentre, randomized, Double-blind, placebo-controlled, Parallel-group, efficacy, and safety study of gantenerumab in patients with Prodromal to mild Alzheimer’s disease
  • ROTEM algorithm for ECMO bleeding - A randomized controlled trial of the safety and feasibility of a rotational thromboelastometry (ROTEM) based algorithm to treat bleeding episodes in extracorporeal membrane oxygenation (ECMO)
  • Safety of metformin in liver disease - The pharmacokinetics and safety of metformin in patients with liver disease
  • SEARCH- C - SurvEillance for Antiviral Resistant variants in Chronic Hepatitis C patients.
  • Sedation Practice in Intensive Care Evaluation: A Randomised Controlled Trial (SPICE RCT) - NSW Sedation Practice in Intensive Care Evaluation: A Prospective Multicentre Randomised Controlled Trial of Early Goal Directed Sedation Compared to Standard Care in Mechanically Ventilated Critically Ill Patients
  • Sexual quality of life of people with HIV and/or Hepatitis C in Australia: A qualitative insight and the development of a sexual life questionnaire - Sexual quality of life of people with HIV and/or Hepatitis C in Australia: A qualitative insight and the development of a sexual life questionnaire
  • SHERLOC - MM-121-01-02-09 - A Phase 2 Study of MM-121 in Combination with Docetaxel versus Docetaxel alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
  • Simplify - A phase II, open-label, single arm, multicentre, international trial of sofosbuvir and GS-5816 for people with chronic hepatitis C virus infection and recent injection drug use.
  • Smart Glasses pII - E-hab activity recording – trialling the second Smart Glasses prototype device
  • Smart Glasses prototype II - E-hab activity recording in rehabilitation - trialling the second Smart Glasses prototype device
  • SMART-C - A phase IIIb, open-label, multicentre, international randomised controlled trial of simplified treatment monitoring for 8 weeks glecaprevir (300mg)/pibrentasvir (120mg) in chronic HCV treatment naïve patients without cirrhosis.
  • SMOC+2017 - A surveillance study in multi-organ cancer prone syndromes
  • SOCRATES PRESERVED - Phase IIb safety and efficacy study of four dose regimens of BAY 1021189 in patients with worsening HF and preserved EF (SOCRATES PRESERVED)
  • SODIUM HF - The long term effects of dietary sodium restriction on clinical outcomes in patients with heart failure.
  • SOMAD - Somatic Mutations in Autoimmune Disease
  • SPACE - Study of Pomalidomide in anal cancer precursors – A Phase 2 study of immunomodulation in people with persistent HPV-associated high grade squamous intraepithelial lesions - Kirby.
  • SPANC - A study of the natural history of anal human papillomavirus infection and anal cellular abnormalities in homosexual men.
  • SPARTAN - A Multi-centre, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer
  • SPARTA-OLE (GTil201-OLE) - An Open-Label, Multicenter Study to Evaluate the Longterm Safety of Weekly Intravenous Alphal-Proteinase Inhibitor (Human), Modified Process 60 mg/kg in Subjects With Pulmonary Emphysema Due to Alphal-Antitrypsin Deficiency
  • Starplus B in FAP (major trial) NSW - The effects of butyrylated high amylose maize starch on polyposis in familial adenomatous polyposis patients
  • STARRT-AKI (NSW) - Standard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI): A Multi-Centre, Randomised, Controlled Trial
  • START - Strategic Timing of AntiRetroviral Treatment
  • Statin VS Switch - Rosuvastatin versus Protease Inhibitor Switching for Hypercholesterolaemia in HIV-infected Adults
  • Statins in Metastatic CRPC - Statins in Metastatic Castration-Resistant Prostate Cancer
  • STELLAR 3 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis.
  • STOP - Determinants of sustained virological response after discontinuation of long-term nucleoside analogue therapy in chronic hepatitis B patients.
  • STop Or REtain - STORE - Impact of stopping sulfonylureas in patients with premix insulin
  • STOP-AUST - The Spot sign and Tranexamic acid On Preventing ICH growth - AUStralasia Trial
  • Stroke Imaging and machine-learning - Extracting novel insights from clinically acquired neuroimaging data to explore impairment and recovery post-stroke: investigating a new analytical pathway via machine-learning
  • Study to compare a dolutegravir-based two-drug HIV regimen with a standard dolutegravir-based three-drug regimen - A Phase III, randomised, double-blind, multicentre, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected treatment-naive adults
  • SVH Australasian Resuscitation In Sepsis Evaluation (ARISE) - A multi-centre randomised controlled trial of early goal-directed therapy in patients presenting to the Emergency Department with severe sepsis in Australasia
  • SVH Interim-PET/CT-directed Therapy in DLBCL - Early Treatment Intensification with R-ICE Chemotherapy Followed by Autologus Stem Cell Transplantation Using Z-BEAM for Patients with Poor Prognosis Diffuse Large B-Cell Lymphoma as Identified by Interim PET/CT Scan Performed After Four Cycles of R-CHOP-14 Chemotherapy
  • Tacrolimus Target AUC Study in Lung Transplantation - Tacrolimus Target AUC Study in Lung Transplantation
  • TAME Cardiac Arrest Trial - Targeted therapeutic mild hypercapnia after resuscitated cardiac arrest: A phase III multicentre randomised controlled trial
  • TARGET3D - An open label, multicentre, international pilot study of paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin for people with recently acquired hepatitis C virus infection with or without HIV co-infection
  • Telerehabilitation for Trauma (TReT) - Investigating the feasibility of a novel telehealth intervention to provide rehabilitation services for patients following trauma.
  • Tendyne - Expanded Clinical Study of the Tendyne Mitral Valve System
  • Test - Test
  • The "Deckled" Incision - A New Approach to Improving Postoperative Scars - The "Deckled" Incision - A New Approach to Improving Postoperative Scars
  • The ASSURE study - A Phase II dose escalation study of cyclophosphamide in haematopoietic stem cell transplantation in severe systemic sclerosis patients unfit for standard dose cyclophosphamide.
  • The Attain Study - A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician’s Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine
  • the BALANCE study - Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness: Randomized Controlled Trial
  • The BEACON CRC Study - A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer
  • The COPS Trial - Colchicine in Patients with Acute Coronary Syndromes
  • The CREDENCE Trial - AR_A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
  • The effect of silicone vs. non-silicone dressings on postoperative scar: a randomized controlled study - The effect of silicone vs. non-silicone dressings on postoperative scar: a randomized controlled study
  • The effect of weekly rifapentine and isoniazid, compared to 9 months of isoniazid, upon adherence with treatment for latent TB infection in Sydney Local Heath District - The effect of weekly rifapentine and isoniazid, compared to 9 months of isoniazid, upon adherence with treatment for latent TB infection in Sydney Local Heath District
  • The Efficacy of Levodopa treatment in Adult Onset Primary Dystonia Patients - A prospective, randomized, double blind, placebo-controlled, crossover study of the effectiveness of Levodopa treatment in Adult Primary Dystonia Patients.
  • The International LDCT Study - Prospective Evaluation of Selection Criteria for Lung Cancer Screening With Low-dose Thoracic Computed Tomography and Standardized System for Nodule Management - An International Study
  • The Lisdex Study - Dose-escalating, phase-2 study of oral lisdexamfetamine in adults with methamphetamine dependence
  • The Online Mindfulness-Enhanced Program for Anxiety and Depression - The Online Mindfulness-Enhanced iCBT Program for Anxiety and Depression: A Pilot Trial and a Randomised Controlled Trial
  • The pharmacokinetics of probe drugs in patients with acute kidney injury - The pharmacokinetics of probe drugs in patients with acute kidney injury
  • The PTSD Program - The PTSD Program - A Randomised Controlled Trial
  • The SPHInX Study - A Multi-Centre Double-Blind Randomised Placebo-Controlled Trial of Oral Anticoagulation with Apixaban in Systemic Sclerosis-Related Pulmonary Arterial Hypertension.
  • The Sweet Spot: five levels of support for an anxiety and depression course plus usual care, compared to usual care alone - A randomised controlled trial comparing five levels of support for an anxiety and depression course plus usual care, to usual care alone.
  • The TARGET Nutrition Study (Amended) - The Augmented versus Routine approach to Giving Energy Trial : A randomised controlled trial
  • TRANSFUSE - STandaRd Issue TrANsfusion versuS Fresher red blood cell Use in intenSive carE (TRANSFUSE) - a randomised controlled trial
  • Transplant rehabilitation audit - A retrospective audit of inpatient rehabilitation following transplantation at St Vincent’s Hospital and Sacred Heart Health
  • TREATT: Trial to EvaluAte Tranexamic acid therapy in Thrombocytopenia - A double blind, randomised controlled trial evaluating the safety and efficacy of Tranexamic acid in patients with haematological malignancies with severe thrombocytopenia.
  • TRESAX - Contribution of T follicular helper cells to maintenance of and recrudescence of virus from the latent HIV-1 reservoir
  • TRITON - The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension, a multicenter, double-blind, placebo controlled Phase 3b study.
  • TTP - Translational neurorehabilitation - a telehealth transfer package to integrate evidence-based research into routine clinical practice post-stroke.
  • ULIS-III - An international, multicentre, observational, prospective, longitudinal cohort study to assess the impact of integrated upper-limb spasticity management including the use of Bont-A injections on patient-centred goal attainment in real life practice - ULIS III
  • UNISoN: anzUp Nivo plus Ipi+nivo Sequential Non-clear cell - Phase II Sequential Treatment Trial Of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab In Metastatic Or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602).
  • Use of TCZ to prevent acute GVHD in HLA-matched patients - randomized Phase III multicentre - A phase III randomized study of humanized anti-IL-6 receptor antibody Tocilizumab (TCZ) to prevent development of acute graft versus host disease (GVHD) post HLA-matched allogeneic haematopoietic progenitor cell transplantation (HPCT).
  • VERICI - Single site, pilot RCT of early in-reach rehabilitation for survivors of critical illness
  • Vitamin D dosing in SIRS - Vitamin D dosing study in Intensive Care Unit (ICU) patients with the Systemic Inflammatory Response Syndrome (SIRS)
  • Wallaman GS-US312-0123 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combinationwith Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia
  • WAVECREST 2 Trial - WAveCrest Vs. Watchman TranssEptal LAA CLosure to REduce AF-Mediated STroke 2
  • Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma - a randomised phase III trial - Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma - a randomised phase III trial
  • WORKING 2GETHER - Proactive in-reach rehabilitation service for all admitted patients with developmental/intellectual disability – a feasibility study of a new shared care model
  • XanADu - A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects with Mild Dementia due to Alzheimer’s Disease (AD).
  • XL184–308 Cabozantinib - A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy
  • Young people and diabetes - Tools for resilience: A mobile phone and web-based intervention for improving mental wellbeing and reducing distress in adolescents and young adults with Type 1 diabetes
  • Zoledronate Versus Tenofovir Switching for Low BMD - ZEST - Bisphosphonate Therapy with Zoledronate or Tenofovir Switching to Improve Low Bone Mineral Density in HIV-Infected Adults: a Strategic, Randomised Trial